Fructose metabolism in pancreatic ductal adenocarcinoma: emerging vulnerabilities in KRAS G12D tumors and therapeutic perspectives with sodium citrate
Pancreatic ductal adenocarcinoma (PDAC) is characterized by profound metabolic plasticity and remains highly resistant to therapy. Activating KRAS mutations occur in approximately 90% of PDACs, with KRAS G12D being the most prevalent variant (~ 35–40%). Recent evidence indicates that KRAS G12D PDAC cells exploit...